Pfizer (PFE) Restructuring Costs (2009 - 2026)
Pfizer (PFE) posted quarterly Restructuring Costs of $49.0 million for Q1 2026, down 92.11% year-over-year from $621.0 million in Q1 2025, and down 84.09% quarter-over-quarter from $308.0 million in Q4 2025.
Pfizer (PFE) Restructuring Costs (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Restructuring Costs for 18 consecutive years, with $49.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Restructuring Costs fell 92.11% year-over-year to $49.0 million; the TTM figure through Mar 2026 stood at $576.0 million (down 83.52% YoY), while the FY2025 annual figure was $1.1 billion, down 54.86% from the prior year.
- Restructuring Costs fell to $49.0 million in Q1 2026 per PFE's latest filing, from $308.0 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $2.6 billion in Q4 2023 and bottomed at -$44.0 million in Q2 2023.
- Historically, Restructuring Costs has averaged $547.2 million across 5 years, with a median of $192.0 million in 2022.
- Annual changes were most pronounced in 2022 — Restructuring Costs surged 19000.0% — and 2023, when it sank 122.92%.
- Pfizer's Restructuring Costs stood at $189.0 million in 2022, then jumped by 1257.67% to $2.6 billion in 2023, then tumbled by 34.96% to $1.7 billion in 2024, then sank by 81.55% to $308.0 million in 2025, then tumbled by 84.09% to $49.0 million in 2026.
- Business Quant data shows PFE's Restructuring Costs at $49.0 million in Q1 2026, $308.0 million in Q4 2025, and $237.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 457.00 Mn |
| Mar 29, 2026 | 49.00 Mn |
| Dec 31, 2025 | 308.00 Mn |
| Sep 28, 2025 | 237.00 Mn |
| Jun 29, 2025 | -18.00 Mn |
| Mar 30, 2025 | 621.00 Mn |
| Sep 29, 2024 | 1.67 Bn |
| Jun 30, 2024 | 1.10 Bn |
| Mar 31, 2024 | 102.00 Mn |
| Dec 31, 2023 | 2.57 Bn |
| Jul 2, 2023 | 138.00 Mn |
| Apr 2, 2023 | -44.00 Mn |
| Jul 3, 2022 | 189.00 Mn |
| Apr 3, 2022 | 192.00 Mn |
| Oct 3, 2021 | 656.00 Mn |
| Jul 4, 2021 | -1.00 Mn |
| Apr 4, 2021 | 22.00 Mn |
| Sep 27, 2020 | 374.00 Mn |
| Jun 28, 2020 | 338.00 Mn |
| Mar 29, 2020 | 54.00 Mn |